← Scisparc overview

Scisparc vs ACADIA Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Scisparc Ltd (SPRC)

Q3 2026
▲4

SciSparc's AI and quantum pivot drives gains, Tourette drug advances

  • Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.

    This is a new strategic direction that changes the company's story and investor appeal.

  • Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.

    This was the period's biggest price catalyst and shows how the quantum story is being received.

  • Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.

    Clinical and regulatory progress on the main drug candidate is a fundamental value driver.

  • CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.

    This is the latest quantum milestone that keeps the technology story alive for investors.

August 2026
▲4

SciSparc's AI and quantum pivot drives gains, Tourette drug advances

  • Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.

    This is a new strategic direction that changes the company's story and investor appeal.

  • Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.

    This was the period's biggest price catalyst and shows how the quantum story is being received.

  • Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.

    Clinical and regulatory progress on the main drug candidate is a fundamental value driver.

  • CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.

    This is the latest quantum milestone that keeps the technology story alive for investors.

Latest
▲4

SciSparc's AI and quantum pivot drives gains, Tourette drug advances

  • Agentic AI pivot opens new growth path SciSparc's board decided to target the agentic AI market and formed an AI and cybersecurity advisory board, while evaluating deals with several AI companies. This signals a strategic shift toward a high-growth tech sector, which can lift SPRC's price by attracting investors betting on a new business line beyond biotech.

    This is a new strategic direction that changes the company's story and investor appeal.

  • Quantum workflow validation sparks 70% surge NeuroThera Labs validated a quantum sampling workflow for clinical trial data on an S&P 500 company's platform, and SPRC shares jumped 70.5% to $9.09. The move shows investors are rewarding the quantum computing angle, though such sharp one-day spikes can fade without follow-through.

    This was the period's biggest price catalyst and shows how the quantum story is being received.

  • Tourette drug advances with Phase IIb and FDA orphan bid NeuroThera started a Phase IIb trial of SCI-110 for Tourette Syndrome at Hannover Medical School and is seeking FDA Orphan Drug Designation, hiring a government affairs firm. Progress on the core drug candidate supports SPRC's value by raising the odds of a future approved product.

    Clinical and regulatory progress on the main drug candidate is a fundamental value driver.

  • CliniQuantum reports 16.8-fold simulation speedup CliniQuantum, majority-owned by NeuroThera, reported a 16.8-fold speedup in quantum simulation on gene data using a GPU. The company itself notes this benchmark does not prove clinical value, so the news supports the tech narrative but is not yet a proven medical or revenue breakthrough.

    This is the latest quantum milestone that keeps the technology story alive for investors.

ACADIA Pharmaceuticals Inc (ACAD)

Q3 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

August 2026
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.

Latest
▲3▼1

Remlifanserin Phase 2 miss cuts Alzheimer's hopes; Daybue still carries ACAD

  • Remlifanserin Phase 2 failure and downgrades ACADIA's remlifanserin failed its Phase 2 primary endpoint in Alzheimer's disease psychosis, and the 30 mg dose is being dropped for lack of efficacy. Goldman reiterated Sell with a $17 target; Citi and BMO cut targets. The stock fell about 13%, as the pipeline's biggest hoped-for catalyst lost credibility.

    This is the period's dominant new event and the main reason ACAD moved.

  • Daybue guidance raised and EU approval won Acadia raised 2026 Daybue sales guidance to $480-$510 million on strong uptake of the STIX formulation, and the European Commission approved Daybue for Rett syndrome — the first such EU approval. This widens the commercial base and partly offsets the pipeline setback.

    It is the main new positive force supporting ACAD's price this period.

  • Analyst fair value and targets lifted on Daybue After the Daybue revenue beat and higher guidance, fair value was raised to $33.25 and several analysts moved targets into the mid-$30s. Citi put the stock on a 90-day upside catalyst watch tied to the remlifanserin readout — a catalyst that has now failed.

    Shows the analyst view that drove ACAD before the trial miss, and the setup that reversed.

  • Fast Track and a large dementia-psychosis market The FDA gave remlifanserin Fast Track status, and a market report projected dementia-related psychosis growing 26.2% a year through 2036, naming ACP-204 as a key therapy. These support the long-term opportunity, though the Phase 2 miss now casts doubt on it.

    Explains the regulatory and demand backdrop behind the remlifanserin story.